Consumer Health Education & Advocacy Training
BlueRipple Health equips you to understand your options for detecting, diagnosing, and treating coronary artery disease — and to advocate for yourself within a system that rewards proactivity.
Portal
The optimal balance between diagnostic accuracy, safety, and cost-effectiveness.
A fundamentally different approach to lowering LDL cholesterol.
The inherited risk factor most doctors never test for.
Banach et al., 2025 · Meta-analysis
Adding ezetimibe to a statin cut cardiovascular events and deaths beyond a statin alone — a combination that is cheap, generic, and underused.
Sehayek et al., 2025 · Systematic review
Across more than 590,000 people, apoB tracked cardiovascular risk more faithfully than LDL-C or non-HDL-C wherever the measures disagreed.
Ryan et al., 2024 · Prespecified analysis of randomized trial
In adults with obesity but not diabetes, semaglutide produced sustained weight loss across four years — without the rebound most diets bring.
Silent atherosclerosis is detectable using imaging in early adulthood, with age- and sex-associated increases in prevalence across arterial territories and significant increases in plaque volume, based on results from the REACT trial presented at ESC Congress 2026 and simultaneously published in NEJM.
Read moreNearly 25 million more adults in the U.S. are eligible for statin therapy, based on recommendations in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, compared with the previous guideline, according to original research published Aug. 12 in JACC.
Read moreThe U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemi
Read moreGet annual access to the Portal — a comprehensive, independent analysis of every option available for coronary artery disease.
Get Annual Access — $199/yr